Abstract 4363276: Efficacy of Anti-inflammatory Therapies for Pericarditis: A Systematic Review and Network Meta-analysis

作者
Mirna Ragheb,Falia Pantieras,Alexander Pearson,Milin Patel,James Lisondra,Sarah May Visintini,Yousef Abumustafa,Omar Ani,Ramtin Hakimjavadi,Vartan Mardigyan,Michael Chetrit,Tahir S Kafil,George Wells,Kevin E. Boczar
出处
期刊:Circulation [Lippincott Williams & Wilkins]
卷期号:152 (Suppl_3)
标识
DOI:10.1161/circ.152.suppl_3.4363276
摘要

Background: One of the most troublesome complications of acute pericarditis is recurrence. Non-steroidal anti-inflammatory drugs (NSAIDs) and colchicine form the cornerstone treatment, with the addition of steroids in cases of incomplete response. Recent evidence also suggests a role for interleukin-1 (IL-1) antagonists in challenging cases of recurrence. However, with an increasing number of potential therapies, our study aims to examine the relative efficacy of these anti-inflammatory treatments for recurrent pericarditis risk reduction. Methods: We searched Medline, Embase, and the Cochrane Central Register of Controlled Trials in October 2023. We included randomized controlled trials (RCTs) and prospective cohort studies of patients with pericarditis treated with a drug with anti-inflammatory properties compared with those treated with a control. The main outcome evaluated was pericarditis recurrence. Results: A total of 6,831 studies were screened, of which 25 articles were included (14 RCTs and 11 cohort studies) for a total number of patients of 3,561. The mean age across studies was 54.82 years for adults and 9.04 years for children (females = 40.55%). The average follow-up duration was 20.03 months. Bayesian network meta-analysis was performed to calculate risk estimates using a random effects model (Figure 1). Goflikicept, a fusion protein that neutralizes IL-1, showed a significant reduction in recurrent pericarditis rates (OR: 0.00, 95% Credible Limits [Crl]: 0.00-0.08). Similarly, anakinra (OR: 0.01, 95% Crl: 0.00-0.13), rilonacept (OR: 0.02, 95% Crl: 0.00-0.22) and colchicine (OR: 0.35, 95% Crl: 0.19-0.64) were associated with a significant reduction in recurrent pericarditis events. High dose colchicine (OR: 0.70, 95% Crl: 0.13-4.12) was not superior to regular dose colchicine (1 mg vs 0.6 mg twice daily, respectively). Interestingly, there was not enough data to make a meaningful comparison between steroids and control. Conclusion: In our analysis, goflikicept, rilonacept, and anakinra were most effective at reducing recurrent pericarditis rates. However, the evidence is based on a small number of studies. Our analysis also corroborated evidence regarding the efficacy of colchicine in reducing pericarditis recurrence. For a comprehensive analysis of the benefits and harms of anti-inflammatory therapies, larger comparative studies or network meta-analyses of patient-level data are required.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
wycpavel完成签到,获得积分10
刚刚
刚刚
英姑的应助被孙朱珠采纳,获得10
刚刚
爆米花的应助被六六采纳,获得10
1秒前
鱼鱼鱼完成签到,获得积分10
1秒前
复杂的傲松完成签到,获得积分10
1秒前
1秒前
L91完成签到,获得积分10
2秒前
朝俞完成签到 ,获得积分10
2秒前
无字诉题发布了新的文献求助10
2秒前
2秒前
2秒前
斯文败类的应助被guoguo采纳,获得10
2秒前
shelemi完成签到,获得积分10
3秒前
3秒前
3秒前
子卿发布了新的文献求助10
4秒前
无限凛完成签到 ,获得积分10
4秒前
vv完成签到,获得积分10
4秒前
4秒前
4秒前
4秒前
5秒前
asdfsdafg发布了新的文献求助10
5秒前
DW的应助被动人的从云采纳,获得10
5秒前
科研通AI6.4的应助被放手一搏采纳,获得10
5秒前
神勇问安完成签到,获得积分10
5秒前
6秒前
6秒前
6秒前
xiaoyi完成签到,获得积分10
6秒前
FZz完成签到 ,获得积分10
6秒前
今夜天将放晴完成签到,获得积分10
6秒前
大方树叶完成签到,获得积分10
7秒前
P1atinum完成签到,获得积分10
7秒前
蓝兰完成签到,获得积分10
7秒前
研友_Zle7a8完成签到,获得积分10
7秒前
尊敬凝荷完成签到,获得积分10
7秒前
Owen的应助被鲸落采纳,获得10
7秒前
甜甜的小虾米完成签到,获得积分10
7秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180275
求助须知:如何正确求助?哪些是违规求助? 9570366
关于积分的说明 21810725
捐赠科研通 7776380
什么是DOI,文献DOI怎么找? 3433277
关于科研通互助平台的介绍 2557483
邀请新用户注册赠送积分活动 2479042